Radiological and Biological Tumoural and Peri-tumoural Factors in Neoadjuvant Endocrine-treated Breast Cancers

• Status: Completed
• Trial end date: 2020-12-24
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to monitor the change in cancer size in women with breast cancer on anti-hormone treatment using different types of assessment including ultrasound scan (US), shearwave elastography (SWE) and magnetic resonance imaging (MRI), and assess how this corresponds to the changes in the cancer biology.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NHS Tayside
• Treatments: Aromatase Inhibitors; Letrozole

Criteria

Inclusion Criteria:

• Postmenopausal women: Defined as >12 months amenorrhoea in absence of medical therapy known to induce this; or bilateral oophorectomy; or if last menses <12 months before starting treatment, FSH >35 IU/L and LH >40 IU/L.

• ER positive (Allred score >3) invasive breast cancer

• Staging as T1-4, N0-2, M0

• Patient agreed to neoadjuvant endocrine therapy as recommended by MDT

• Fresh tissue stored at time of diagnostic core biopsy

• Suitable for, and tolerant of MRI scan

• Fit for surgical intervention at time of entry into study

Exclusion Criteria:

• Premenopausal or unable to determine menopausal status

• Not fit for surgical intervention due to co-morbidities

• Contraindication for MRI (including severe claustrophobia)

• Current use of HRT, or HRT use at time of diagnostic core biopsy